Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $16.67.

A number of analysts recently issued reports on MGX shares. HC Wainwright lifted their price target on shares of Metagenomi from $7.00 to $14.00 and gave the stock a "buy" rating in a research note on Tuesday, December 10th. Chardan Capital reiterated a "buy" rating and set a $15.00 target price on shares of Metagenomi in a research note on Wednesday, November 20th.

Hedge Funds Weigh In On Metagenomi

Several institutional investors have recently modified their holdings of the company. Novo Holdings A S lifted its holdings in Metagenomi by 3.5% in the second quarter. Novo Holdings A S now owns 1,800,000 shares of the company's stock worth $7,344,000 after purchasing an additional 60,825 shares during the period. Geode Capital Management LLC raised its holdings in Metagenomi by 105.8% during the 3rd quarter. Geode Capital Management LLC now owns 338,031 shares of the company's stock worth $734,000 after buying an additional 173,796 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in shares of Metagenomi by 209.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company's stock valued at $296,000 after purchasing an additional 92,468 shares during the period. Fortitude Advisory Group L.L.C. acquired a new position in shares of Metagenomi in the 4th quarter valued at about $273,000. Finally, Spire Wealth Management acquired a new position in Metagenomi in the fourth quarter worth approximately $267,000.

Metagenomi Stock Up 1.0 %

Shares of NASDAQ:MGX traded up $0.03 during midday trading on Friday, reaching $3.00. The company had a trading volume of 880,071 shares, compared to its average volume of 2,211,250. The stock's fifty day moving average price is $2.90 and its 200-day moving average price is $2.92. Metagenomi has a one year low of $1.61 and a one year high of $12.74.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.